2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisCharacteristics of patientsC-peptide levelsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2006
Trends in Fetal Echocardiography and Implications for Clinical Practice
Hamar BD, Dziura J, Friedman A, Kleinman CS, Copel JA. Trends in Fetal Echocardiography and Implications for Clinical Practice. Journal Of Ultrasound In Medicine 2006, 25: 197-202. PMID: 16439782, DOI: 10.7863/jum.2006.25.2.197.Peer-Reviewed Original ResearchConceptsStructural congenital heart diseaseCongenital heart diseaseYale-New Haven HospitalFetal echocardiographyProportion of studiesStudy periodPattern of indicationsPatterns of referralObstetric demographicsNonimmune hydropsObstetric careReferral patternsPrimary indicationSubgroup analysisHeart diseaseFamily historyFetal anomaliesFetal arrhythmiasCardiac diseaseLarge seriesClinical practiceDiabetesTeratogen exposurePrevious childMantel-Haenszel